AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04553120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternating single stimulus and multiple stimuli
Description: P-ARET for cockroach phobia alternating between two interventions: exposure to a single stimulus (always using the same projected cockroach) and exposure to multiple stimuli (different cockroaches in terms of number, shape, colour and movement). It will be counterbalanced to start the same number of participants in each of the two modalities. The two conditions will be randomly applied for each participant, with the restriction of that each condition will be applied 3 times.~There will be 6 weekly sessions of approximately 1 hour. The purpose of this exposure treatment is to confront patients to the phobic stimuli in a controlled manner, which favors the habituation process and allows them to accept that the negative consequences they fear do not actually occur. All exposure sessions should be recorded (patients will sign informed consent for recording prior to treatment initiation).
Study NCT03476499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Imaging (NIR) device
Description: Handheld near infrared multispectral imaging device with custom software.
Study NCT01952561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine ring
Study NCT02114320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-BD
Description: EUS-guided hepaticogastrostomy (EUS-HG) will be performed in patients with hilar stricture or altered anatomy such as Roux-en-Y anastomosis, and EUS-guided choledochoduodenostomy (EUS-CD) will be performed in patients with mid to distal extrahepatic bile duct strictures. Because EUS-guided rendezvous technique can be attempted only in patients in whom the papilla is endoscopically accessible. Following bile duct puncture using a 19-gauge fine needle, one-step or graded tract dilatation will be performed. Then, finally we insert a partially or fully covered metallic stent.
Study NCT00203099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate, N-Acetylcysteine
Description: Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
Study NCT04721886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonsgraphy
Description: Undergo ultrasonography
Study NCT04721886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microcpheres
Description: Given IV
Study NCT04721886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast - Enhanced Ultrasound
Description: Undergo CEUS
Study NCT03566134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-8010 Placebo
Description: Participants receive placebo to match DA-8010 orally once a day.
Study NCT03566134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA-8010 Placebo
Description: Participants receive placebo to match DA-8010 orally once a day.
Study NCT03566134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 2.5mg
Description: Participants receive DA-8010 2.5mg orally once a day.
Study NCT03566134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 5mg
Description: Participants receive DA-8010 5mg orally once a day.
Study NCT03566134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin 5mg
Description: Participants receive solifenacin 5 mg orally once a day.
Study NCT03566134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate placebo
Description: Participants receive placebo to match solifenacin 5 mg orally once a day.
Study NCT03566134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solifenacin succinate placebo
Description: Participants receive placebo to match solifenacin 5 mg orally once a day.
Study NCT04178668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral mucosa and saliva samples
Description: one oral mucosa sample and one saliva sample
Study NCT04193995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday, and fasting is terminated at 0800 on Monday and Thursday. Medications may be adjusted as needed during these visits, and this is reconsidered and may be further adjusted after the receipt of the blood tests results later during the day. Adjustments based on lab results are discussed with the patients during the clinic visit or later on the same day. Also, dietary needs are addressed by the physician and /or the dietician, during the clinic visit. As of week 3 through week 12, clinic visit is reduced to once a week, on Thursdays.
Study NCT02832115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Nitroglycerine
Description: Topical nitroglycerine is applied to wrist prior to transradial cardiac catheterization to dilate radial artery and reduce spasm in study arm patients
Study NCT02832115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Lidocaine
Description: Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms
Study NCT02832115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Lidocaine
Description: Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms
Study NCT02919995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: RPL554 suspension administered using a nebuliser
Study NCT02919995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution administered using a nebuliser
Study NCT01887457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VFEND
Description: voriconazole will be administered in iv form
Study NCT04491318 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
Study NCT03319147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: 4g of essential amino acids
Study NCT03319147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4g of maltdextrin
Study NCT00594841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation of AC joint dislocation
Description: Definitive surgical treatment (i.e., ORIF) will be performed within 28 days of the injury. In all cases the procedure will be performed by an orthopedic staff surgeon with the assistance of a fellow/resident(s). The operating surgeon will determine the positioning of the patient for surgery. ORIF of the AC joint dislocation will be carried out as follows:~* Anatomic reduction of the AC joint~* Definitive fixation with a hook plate and screws
Study NCT00594841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non operative treatment of AC joint dislocation (sling)
Description: Standard protocol for conservative treatment will consist of the implementation of a sling, for shoulder support and patient comfort, for four weeks followed by physiotherapy. Pendulum exercises may be implemented at any time as dictated by the attending surgeon.
Study NCT03818321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine Hippurate 1 g tablet
Description: Methenamine Hippurate (study drug) is an FDA approved medication in the prevention of UTI. Methenamine Hippurate 1g contains Hippuric acid salt of Methenamine (hexamethylene tetramine), Magnesium Stearate, Povidone, Saccharin Sodium, FD\&C Yellow No. 5 (tartrazine) (www.iodine.com/drug/hiprex/fda-package-insert).
Study NCT03818321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient.
Study NCT02196636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo, administered orally with approximately 240 mL of buffer
Study NCT02196636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6806127
Description: Administered orally with approximately 240 mL of buffer
Study NCT05827172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation
Description: The aim of the ablation procedure was to achieve isolation of all pulmonary veins and to restore sinus rhythm.Additional ablation strategies were made at the discretion of the operators.
Study NCT05827172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: medical therapy
Description: The medical therapy for atrial fibrillation was administered in accordance with the guidelines that were available at the time of the trial.Efforts to maintain sinus rhythm were recommended. The aim of the treatment was a ventricular rate of 60 to 80 beats per minute at rest.
Study NCT01035125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program
Description: Participants will receive a one week inpatient self-management program
Study NCT01249261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 5 mg/day
Study NCT01249261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Risedronate
Description: placebo years 1-5 followed by 5 mg risedronate years 6 \& 7 and no drug year 8
Study NCT03324087 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HRQoL
Description: use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
Study NCT03758040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slips on Turns
Description: Subjects will be administered a slip at 3 different times in the gait cycle for each of 3 different patch curvatures and 2 different legs for a total of 18 slip episodes. Slips will be delivered while walking along a straight path (infinite radius), or curved paths with radii 2, or 1 meters.
Study NCT03758040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slips on Slopes
Description: Slips will be administered at 3 different times in the gait cycle over sloped ground surface of no slope, ±5.0 and ±10.0 degrees slopes in the direction of walking, and 5.0 and 10.0 degrees perpendicular to the direction of walking. On slopes perpendicular to the direction of walking, slips will be administered to the uphill or downhill foot. A total of 27 slip episodes will be administered. Sloped walking surfaces will be generated with the CAREN system treadmill.
Study NCT01441076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra/Kineret\[registered\] is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra)
Study NCT02955667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: invivo microscopy group
Description: patients receive invivo micro-colposcopy examination
Study NCT02955667 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: normal group
Description: patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
Study NCT02559141 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dobutamine
Description: If PPV ≤10%, volume substitution of 500 ml of crystalloids and/or colloids as long as CI was ≥2.5 l/min/m². Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg was achieved by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min).
Study NCT01099462 — intervention group
Intervention type: DRUG
Intervention: Ibuprofen
Description: Ibuprofen (10mg/kg BW) will be given orally if the temperature on presentation is higher than 38.0OC according to the decision of the attending physician.
Study NCT02947789 — intervention group
Intervention type: PROCEDURE
Intervention: Emergency surgery
Description: Patients undergoing emergency surgery
Study NCT02892448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance imaging (CMR)
Description: Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.
Study NCT01153932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968
Description: Subcutaneous injection
Study NCT01153932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matched placebo
Description: Subcutaneous injection
Study NCT02058303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Forearm block
Description: 20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
Study NCT02058303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine supraclavicular block
Description: 20-30mL 0.5% bupivacaine
Study NCT05741671 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.
Study NCT00089362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvespimycin hydrochloride
Description: Given IV
Study NCT00089362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00089362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02094690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therabite
Description: 10 repetitions holding Therabite for 30 seconds. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
Study NCT02094690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperboloid
Description: 5 min of bilateral mastication alternated with hyperboloid. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
Study NCT02866279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel Contraceptive Implant
Description: Women will be randomized to the TIMING of implant placement
Study NCT02866279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etonogestrel Contraceptive Implant
Description: Women will be randomized to the TIMING of implant placement
Study NCT00553709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
Study NCT00553709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine
Description: Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
Study NCT04501185 — intervention group
Intervention type: DEVICE
Intervention: total hip arthroplasty
Description: The indication for total hip arthroplasty is mainly osteoarthritis.
Study NCT04194528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen 5/325 mg
Description: The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
Study NCT04194528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proteus digital medicine program
Description: The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
Study NCT00271817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ezetimibe/simvastatin + niacin (ER)
Description: ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
Study NCT00271817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo to ezetimibe/simvastatin
Description: ezetimibe/simvastatin (Pbo) tablet. Treatment time will be \~24 weeks.
Study NCT00271817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: niacin (ER) tablet
Description: niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
Study NCT00271817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ezetimibe (+) simvastatin
Description: ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~24 weeks.
Study NCT00271817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo to Niacin (ER)
Description: Niacin (ER) (Pbo) tablet. Treatment time will be \~24 weeks.
Study NCT00271817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ezetimibe/simvastatin and niacin (ER)
Description: ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be \~40 additional weeks for a total of 64 weeks
Study NCT00271817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: ezetimibe and simvastatin
Description: ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
Study NCT00271817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to niacin (ER)
Description: Niacin (ER) (Pbo) tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
Study NCT03767023 — intervention group
Intervention type: OTHER
Intervention: cross sectional
Study NCT02954497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical placement of the Jarvik 2015 VAD
Description: The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
Study NCT02954497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Placement of Jarvik 2015 VAD
Description: Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
Study NCT02662621 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Study NCT02662621 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urine samples
Study NCT05004636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty
Description: Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate (0.3mL) in the block and the other half will receive 0.3 mL of saline in the block.
Study NCT04375202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 1 MG Oral Tablet
Description: Tablets for oral administration, containing 1 mg of the active ingredient colchicine, administered 0.5 mg po every 8 hours x 30 days.
Study NCT01049685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First-line Antiretroviral Therapy
Description: * Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background~* Efavirenz: 01 capsules day, plus NRTI background
Study NCT04772495 — intervention group
Intervention type: GENETIC
Intervention: miRNA
Description: miRNA effect on Multiple sclerosis pathology
Study NCT02581202 — intervention group
Intervention type: DRUG
Intervention: lopinavir/ritonavir
Description: tablet
Study NCT02581202 — intervention group
Intervention type: DRUG
Intervention: lamivudine
Description: tablet
Study NCT01632462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3
Description: This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks.